TransCode Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process Intended to Maximize Value of TTX-MC138 and its Oncology Portfolio

Transcode Therapeutics, Inc. (RNAZ) filed an SEC Form 8-K — Other Events. Exhibit 99.1 TransCode Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process Intended to Maximize Value of TTX-MC138 and its Oncology Portfolio Lead program TTX-MC138 is in Phase 2a clinical development for ctDNA-positive colorectal cancer following curative-int

Event · M&A · announced
Original reporting
Published Oct 28, 2026, 8:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 8:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$RNAZ
Bearish
high confidence
Mentioned
$RNAZ
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$RNAZBearishLow
01

Why it matters

The filing signals a possible change in ownership or partnership structure, creating short‑term uncertainty but also a long‑term upside if a deal materializes.

02

Market read

Primary micro‑cap biotech news; limited immediate market impact but relevant for investors tracking RNA‑based oncology pipelines.

03

What to watch

Potential cash infusion from a partnership could improve runway, offsetting dilution concerns.

Relevance 5/10Novelty 6/10Timing: immediate filing today

Background

Transcode Therapeutics (NASDAQ:RNAZ) is a clinical‑stage biotech developing RNA‑based cancer therapies. The company’s lead candidate TTX‑MC138 recently entered a Phase 2a trial.

Company-level read

Ticker impact

$RNAZBearishHigh confidence
Context

Transcode Therapeutics filed an 8‑K announcing a formal strategic process to evaluate licensing, partnership or sale options for its lead candidate TTX‑MC138 and other oncology assets.

Expected impact

likely pressure as investors price in execution risk and possible dilution from a future transaction.

Evidence & confidence

First‑report of a strategic review without a concrete deal often triggers short‑term sell‑side pressure, especially for a micro‑cap biotech.

Market effects

May signal heightened M&A interest in RNA‑based oncology assets, prompting peers to watch for similar processes.

Limited to US biotech micro‑cap space; no broader regional effect.

Minimal; primarily affects niche biotech investors.

Counterpoint

If the strategic review leads to a high‑value partnership, the stock could rally on upside potential.

Key entities

  • Transcode Therapeutics

    Clinical‑stage biotech developing RNA‑based oncology therapeutics.

  • Tungsten Advisors

    Exclusive strategic financial advisor engaged to lead the process.

  • Natera, Inc.

    Partner for patient enrollment using the Signatera test.

Related articles

$RNAZMedAI 8/10

TransCode presents phase 1a trial data for cancer therapy

TransCode Therapeutics (RNAZ) presented Phase 1a trial data for TTX-MC138 at ESMO Congress 2026. The study met safety endpoints, showed dose-dependent exposure, and indicated disease stabilization and extended progression-free intervals in some patients. TTX-MC138 is being evaluated in a Phase 2a trial under the PRE-I-SPY program.

$NTRAMed

Natera partners with TransCode for cancer trial enrollment

Natera Inc. (NTRA) and TransCode Therapeutics Inc. (RNAZ) announced a collaboration to enroll patients in a colorectal cancer clinical trial using Natera's Signatera test to identify eligible patients. The trial targets patients at risk of recurrence but with no approved therapies. TransCode's TTX-MC138 aims to inhibit a biomarker linked to metastatic cancers. The trial is part of the PRE-I-SPY program and is registered at clinicaltrials.gov.

$RNAZMedAI 8/10

TransCode Reports Continued Disease Stabilization and Extended Treatment Duration with TTX-MC138 in Ongoing Phase 1a Clinical Trial Follow-Up

Transcode Therapeutics, Inc. (RNAZ) filed an SEC Form 8-K — Other Events. Exhibit 99.1 TransCode Reports Continued Disease Stabilization and Extended Treatment Duration with TTX-MC138 in Ongoing Phase 1a Clinical Trial Follow-Up Updated clinical data reinforces evidence of antitumor activity in heavily pretreated patients with advanced solid tumors · I

$VRAXMed

Top Biotech Gainers: VRAX Jumps 100% After Fosun Deal, FBRX Soars On Vitiligo Data, TRAX On Watch

Biotech stocks rose on company-specific catalysts. Virax Biolabs (VRAX) jumped over 100% after signing an exclusive multi-country supply agreement with Fosun Diagnostics for ImmuneSelect. Forte Biosciences (FBRX) gained about 78% on positive Phase 1b vitiligo data for FB102. First Tracks (TRAX) rose ~56% without news. TransCode (RNAZ) and Connect Biopharma (CNTB) also climbed; Sanuwave (SNWV) fell guidance and expects Q2 revenue of $8.5m to $9.5m.

$PBLSMed

Top Biotech Gainers: PBLS Soars Over 50%, CLOV Rallies On Legal Win, RNAZ, TMCI On Watch

Biotech stocks rose on varied catalysts. Parabilis (PBLS) debuted on Nasdaq, up 58% to $31.60 after pricing a $20.00 IPO of 33.5M shares for ~$670M gross proceeds. Clover Health (CLOV) gained 14% to $4.89 after a court ruling upgraded its 2026 PPO Star Rating to 4.5 from 3.5. Myomo (MYO) rose 17% to $1.54; Shoulder Innovations (SI) up 17% to $17.89; GMRS up 13% to $13.18.